News

Argentum Pharmaceuticals Succeeds in Starting Patent Cancellation Trial Against UCB’s VIMPAT®

NEW YORK, May 23, 2016 /PRNewswire/ — Today, the U.S. Patent & Trademark Office (PTO) granted Argentum Pharmaceuticals LLC’s petition for inter partes review (IPR) against all claims of the sole remaining patent listed as covering UCB Inc.’s VIMPAT®(lacosamide) drug in the Food & Drug Administration’s Orange Book.  The PTO concluded that Argentum has established a “reasonable likelihood that it would prevail in showing that claims 1-13 of the ‘551 patent [U.S. Patent RE 38,551] are unpatentable.”  The decision marks the beginning of an IPR trial that will be conducted by three specialist patent judges within the PTO’s Patent Trial & Appeal Board.  A final decision on patentability in the IPR is due within 1 year.

In addition to Argentum’s instituted IPR, Argentum also filed an ex parte reexamination request against this same patent that raises additional grounds of unpatentability than those in the IPR.  A decision by the PTO on Argentum’s reexamination request is due no later than July 29, 2016.

Unlike today’s successful institution of Argentum’s IPR petition, a prior IPR petition filed by a group of generic companies against this same patent was denied in January 2015.  Those companies were Actavis, Inc., Actavis Laboratories FL, Inc., Actavis Pharma, Inc., Amneal Pharmaceuticals, LLC, Amneal Pharmaceuticals of New York, LLC, Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Breckenridge Pharmaceutical, Inc., Vennoot Pharmaceuticals, LLC, Sandoz Inc., Sun Pharma Global FZE, and Sun Pharmaceutical Industries, Ltd.

About Argentum Pharmaceuticals

Argentum is a generic drug company with core competencies in intellectual property and pharmaceutical operations. By working with branded and generic pharmaceutical companies and healthcare payors, Argentum intends to reduce the overall cost of prescription drugs by challenging patents that are not innovative and which artificially support high drug prices. http://www.argentumpharmaceuticals.com

http://www.prnewswire.com/news-releases/argentum-pharmaceuticals-succeeds-in-starting-patent-cancellation-trial-against-ucbs-vimpat-300273542.html

KVK Tech And Argentum Pharmaceuticals Announce Partnership To Commercialize Pharmaceutical Products Made In The U.S.A.

NEW YORK, Feb. 1, 2016 /PRNewswire/ — Argentum has entered into a nonexclusive collaboration agreement with KVK Tech to launch and commercialize pharmaceutical products.  KVK is a recognized leader in the development and manufacture of high-quality, FDA-approved medicines, and possesses operational expertise in pharmaceutical manufacturing, packaging, sales, distribution, research & development, and customer service. KVK’s expertise runs the gamut and includes solid oral, powder, liquid, and proprietary dosage technologies.  KVK is in the process of expanding its capabilities into aseptic products as well with a 225,000 sq./ft. sterile injectable being qualified this year.  KVK takes pride in its ability to advance medical care and offer low-cost, high-quality alternatives in response to today’s healthcare challenges.  KVK is one of the few manufacturers of generic pharmaceuticals who handles all manufacturing, packaging, and distribution in the United States.

To learn more about KVK, please go to www.kvktech.com

MADE IN AMERICA

All KVK Tech products are made in the USA in strictest accordance with FDA, DEA, and DEP guidelines

About Argentum Pharmaceuticals
Argentum is a generic drug company with core competencies in intellectual property and pharmaceutical operations. By working with branded and generic pharmaceutical companies and healthcare payors, Argentum intends to reduce the overall cost of prescription drugs by challenging patents that are not innovative and which artificially support high drug prices.

http://www.prnewswire.com/news-releases/kvk-tech-and-argentum-pharmaceuticals-announce-partnership-to-commercialize-pharmaceutical-products-made-in-the-usa-300213451.html